Litcius/Paper detail

Resolvin E1 Attenuates Chronic Pain-Induced Depression-Like Behavior in Mice: Possible Involvement of Chemerin Receptor ChemR23

Hiroe Suzuki, Takahisa Otsuka, Natsuko HitoraーImamura, Kohei Ishimura, Hayato Fukuda, Koichi Fujiwara, Satoshi Shuto, Satoshi Deyama, Masabumi Minami

2021Biological and Pharmaceutical Bulletin17 citationsDOIOpen Access PDF

Abstract

The antidepressant effect of eicosapentaenoic acid-derived bioactive lipid, resolvin E1 (RvE1), was examined in a murine model of chronic pain-induced depression using a tail suspension test. Because RvE1 reportedly possesses agonistic activity on a chemerin receptor ChemR23, we also examined the antidepressant effect of chemerin. Two weeks after surgery for unilateral spared nerve injury to prepare neuropathic pain model mice, immobility time was measured in a tail suspension test. Chronic pain significantly increased immobility time, and this depression-like behavior was attenuated by intracerebroventricular injection of RvE1 (1 ng) or chemerin (500 ng). These results demonstrate that RvE1 exerts an antidepressant effect in a murine model of chronic pain-induced depression, which is likely to be via ChemR23. RvE1 and its receptor may be promising targets to develop novel antidepressants.

Topics & Concepts

ChemerinTail suspension testAntidepressantChronic painBehavioural despair testNeuropathic painDepression (economics)MedicinePharmacologyReceptorInternal medicineEndocrinologyPsychiatryAdipokineInsulin resistanceInsulinHippocampusEconomicsMacroeconomicsPain Mechanisms and TreatmentsFibromyalgia and Chronic Fatigue Syndrome ResearchPain Management and Placebo Effect
Resolvin E1 Attenuates Chronic Pain-Induced Depression-Like Behavior in Mice: Possible Involvement of Chemerin Receptor ChemR23 | Litcius